Cover Image
市場調查報告書

癲癇: 開發平台分析

Epilepsy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232793
出版日期 內容資訊 英文 421 Pages
訂單完成後即時交付
價格
Back to Top
癲癇: 開發平台分析 Epilepsy - Pipeline Review, H2 2016
出版日期: 2016年08月24日 內容資訊: 英文 421 Pages
簡介

癲癇,特徵是由於腦的神經細胞的集合而產生異常信號傳達的神經病變,引起發作。這個障礙,感覺會突然消失,短時間沒有意識,出現痙攣。癲癇的主要原因,是出生時低氧,生產時或青年時期的事故造成頭部受傷,腦瘤,結節性硬化症等與腦損傷造成的遺傳基因Disease,腦膜炎和腦炎等感染疾病,中風和其他腦功能障礙等。主要的症侯,是重複發作,及四肢無力感,焦慮,意識喪失,肌肉的收縮或痙攣等。

本報告提供癲癇的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 調查範圍
  • 癲癇概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

  • Acorda Therapeutics, Inc.
  • Adamas Pharmaceuticals, Inc.
  • Advicenne Pharma
  • Aeolus Pharmaceuticals, Inc.
  • Aequus Pharmaceuticals Inc.
  • Aestus Therapeutics, Inc.
  • Alexza Pharmaceuticals, Inc.
  • Anavex Life Sciences Corp.
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Bial - Portela & Ca, S.A.
  • BioCrea GmbH
  • Biogen, Inc.
  • Bionomics Limited
  • Biovista Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Catalyst Pharmaceutical Partners, Inc.
  • Chong Kun Dang Pharmaceutical Corp.
  • D-Pharm Ltd.
  • Eisai
  • Grifols, S.A.
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • Hyundai Pharmaceutical Co., Ltd.
  • INSYS Therapeutics, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Iproteos S.L.
  • Johnson & Johnson
  • Knopp Biosciences LLC
  • Lipicard Technologies Limited
  • Marathon Pharmaceuticals, LLC
  • Marinus Pharmaceuticals, Inc.
  • MedGenesis Therapeutix Inc.
  • Nemus Bioscience, Inc.
  • Neurelis, Inc.
  • Neurocrine Biosciences, Inc.
  • Neuron Biopharma SA
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • PharmatrophiX, Inc.
  • Promius Pharma, LLC
  • PTC Therapeutics, Inc.
  • Retrophin Inc.
  • RODES Inc.
  • Sage Therapeutics, Inc.
  • Saniona AB
  • SciFluor Life Sciences, LLC
  • SK Biopharmaceuticals Co., Ltd.
  • 大日本住友製藥
  • 武田藥品工業
  • Trillium Therapeutics Inc.
  • Turing Pharmaceuticals AG
  • UCB S.A.
  • Ultragenyx Pharmaceutical Inc.
  • Upsher-Smith Laboratories, Inc.
  • Vichem Chemie Research Ltd.
  • VistaGen Therapeutics , Inc.
  • Xenon Pharmaceuticals Inc.
  • XERIS Pharmaceuticals, Inc.
  • Zogenix, Inc.
  • Zynerba Pharmaceuticals, Inc.

治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 2-DG
  • ADS-4101
  • ADV-6208
  • ADV-6770
  • AEOL-1114B
  • AEOL-11203
  • AEOL-11207
  • arupurazoramu
  • AMPX-0079
  • ANAVEX-273
  • ataluren
  • AV-101
  • AVL-5189
  • BIS-001
  • BNP-TLE
  • BPS-015 SR
  • buribarasetamu
  • BVA-601
  • 大麻二酚
  • 卡馬西平
  • CCG-63802
  • 中樞神經系統障礙用細胞療法
  • CHEC-9
  • CKD-903
  • clobazam
  • CNV-1061436
  • cosyntropin
  • CPP-115
  • CUR-1916
  • Diazepam
  • DP-VPA
  • 癲癇治療藥
  • 癲癇、行動障礙用MAPK抑制劑
  • Epidiolex
  • eslicarbazepine acetate
  • Everolimus
  • fenfluramine hydrochloride
  • fosphenytoin sodium
  • ganaxolone
  • 癲癇用神經肽 Y 受體 Y2、Y5活性遺傳基因療法
  • GWP-42006
  • 組織胺二鹽酸鹽
  • 人類免疫球蛋白
  • INV-170
  • IPR-131
  • IPR-96
  • IPRO-003
  • JNJ-40411813
  • KM-113
  • KM-314
  • lacosamide
  • lamotrigine
  • levetiracetam
  • liatermin
  • LM22A-4
  • lorazepam
  • LSPGR-1
  • LT-4121
  • LT-4122
  • LT-4123
  • LT-4124
  • LT-4125
  • LT-4126
  • magnesium valproate hydrate
  • MB-003
  • midazolam hydrochloride
  • MP-101
  • MRS-5474
  • naluzotan hydrochloride
  • NB-23R1
  • NGT-168
  • NH-34
  • NRP-2945
  • NST-0037
  • NST-0076
  • Dravet症候群用寡核苷酸
  • perampanel
  • Pregabalin
  • propofol hemisuccinate
  • SAGE-217
  • SAGE-689
  • SCT-66
  • selurampanel
  • sepranolone
  • SF-0034
  • SGE-872
  • 辛伐他汀(simvastatin)
  • 癌症性疼痛、癲癇用鈉流通管道阻斷劑 1
  • 癲癇用小分子 2
  • 癌症性疼痛、癲癇用鈉流通管道阻斷劑 2
  • 癲癇用小分子 3
  • 鈉流通管道阻斷劑 癌症性疼痛、癲癇用小分子 3
  • 癲癇用小分子 4
  • 癲癇用小分子
  • 中風、癲癇用小分子
  • 癲癇、疼痛用 Activate Kv7.2/Kv7.3通道活化劑
  • 癲癇用 GABAA受體次單元α-4/γ促效劑
  • 神經疾病用 mGluR5/mGluR6拮抗劑
  • Dravet症候群用 Nav1.6阻斷劑
  • 偏頭痛、癲癇重積症用 GABA 轉氨酶抑制劑
  • 癲癇用小分子 1
  • 癲癇用小分子 2
  • 癲癇用小分子 3
  • 癲癇用小分子 4
  • 中樞神經系統障礙用小分子
  • 癲癇用小分子
  • 發作用小分子
  • 中樞神經用 GABAA受體活化劑/NMDA受體拮抗劑
  • 神經病變痛、癲癇、耳鳴用 Kv7活化劑
  • 中樞神經、代謝障礙耳鼻喉科的病期用 TrkB受體活化劑
  • 癲癇用GABA-A 受體激動劑
  • 癲癇、自閉症用 GABAA-Beta 2受體激動劑
  • 中樞神經系統障礙用 TLR-4拮抗劑
  • 癲癇、腫瘤學用Dynamin抑制劑
  • 腸漏症候群用電位開口型鈉流通管道抑制劑
  • sulthiame
  • TAK-935
  • TF-0081
  • TG-4155
  • topiramate
  • TRP-001
  • TUR-004
  • TUR-005
  • UCB-0942
  • UX-007
  • VAD-1
  • VAD-2
  • VB-3323
  • VID-45110
  • VU-0456810
  • YKP-3089
  • Z-944
  • ZYN-002
  • ■最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8401IDB

Summary

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2016', provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Epilepsy
  • The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
  • The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Epilepsy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Epilepsy Overview
  • Therapeutics Development
  • Epilepsy - Therapeutics under Development by Companies
  • Epilepsy - Therapeutics under Investigation by Universities/Institutes
  • Epilepsy - Pipeline Products Glance
  • Epilepsy - Products under Development by Companies
  • Epilepsy - Products under Investigation by Universities/Institutes
  • Epilepsy - Companies Involved in Therapeutics Development
  • Epilepsy - Therapeutics Assessment
  • Drug Profiles
  • Epilepsy - Dormant Projects
  • Epilepsy - Discontinued Products
  • Epilepsy - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Epilepsy, H2 2016
  • Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Advicenne, H2 2016
  • Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2016
  • Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2016
  • Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016
  • Epilepsy - Pipeline by Astellas Pharma Inc., H2 2016
  • Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2016
  • Epilepsy - Pipeline by BioCrea GmbH, H2 2016
  • Epilepsy - Pipeline by Biogen Inc, H2 2016
  • Epilepsy - Pipeline by Bionomics Limited, H2 2016
  • Epilepsy - Pipeline by Biovista Inc., H2 2016
  • Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by D-Pharm Ltd., H2 2016
  • Epilepsy - Pipeline by Eisai Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Glialogix, Inc., H2 2016
  • Epilepsy - Pipeline by Grifols, S.A., H2 2016
  • Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2016
  • Epilepsy - Pipeline by H. Lundbeck A/S, H2 2016
  • Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
  • Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Iproteos S.L., H2 2016
  • Epilepsy - Pipeline by Johnson & Johnson, H2 2016
  • Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2016
  • Epilepsy - Pipeline by Lead Discovery Center GmbH, H2 2016
  • Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2016
  • Epilepsy - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
  • Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Neurelis, Inc., H2 2016
  • Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2016
  • Epilepsy - Pipeline by Neuron Biopharma SA, H2 2016
  • Epilepsy - Pipeline by Novartis AG, H2 2016
  • Epilepsy - Pipeline by OPKO Health, Inc., H2 2016
  • Epilepsy - Pipeline by Ovid Therapeutics Inc., H2 2016
  • Epilepsy - Pipeline by Pfizer Inc., H2 2016
  • Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2016
  • Epilepsy - Pipeline by Promius Pharma, LLC, H2 2016
  • Epilepsy - Pipeline by PTC Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Retrophin Inc., H2 2016
  • Epilepsy - Pipeline by Sage Therapeutics, Inc., H2 2016
  • Epilepsy - Pipeline by Saniona AB, H2 2016
  • Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2016
  • Epilepsy - Pipeline by Shire Plc, H2 2016
  • Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Suda Ltd, H2 2016
  • Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
  • Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Epilepsy - Pipeline by Trillium Therapeutics Inc., H2 2016
  • Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Epilepsy - Pipeline by UCB S.A., H2 2016
  • Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016
  • Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016
  • Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2016
  • Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2016
  • Epilepsy - Pipeline by Vitality Biopharma Inc, H2 2016
  • Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2016
  • Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
  • Epilepsy - Pipeline by Zogenix, Inc., H2 2016
  • Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Epilepsy - Dormant Projects, H2 2016
  • Epilepsy - Dormant Projects (Contd..1), H2 2016
  • Epilepsy - Dormant Projects (Contd..2), H2 2016
  • Epilepsy - Dormant Projects (Contd..3), H2 2016
  • Epilepsy - Dormant Projects (Contd..4), H2 2016
  • Epilepsy - Dormant Projects (Contd..5), H2 2016
  • Epilepsy - Dormant Projects (Contd..6), H2 2016
  • Epilepsy - Dormant Projects (Contd..7), H2 2016
  • Epilepsy - Dormant Projects (Contd..8), H2 2016
  • Epilepsy - Dormant Projects (Contd..9), H2 2016
  • Epilepsy - Discontinued Products, H2 2016
  • Epilepsy - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Epilepsy, H2 2016
  • Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top